Nephrology & Urology Devices Market by Product (Catheters, Dialysis Devices, Endoscopes), Technology (Acoustic Wave Technologies, Electrochemical Technologies, Laser Technologies), Distribution Channel, Application, End User - Global Forecast 2025-2032
Description
The Nephrology & Urology Devices Market was valued at USD 17.38 billion in 2024 and is projected to grow to USD 19.36 billion in 2025, with a CAGR of 11.46%, reaching USD 41.42 billion by 2032.
A concise orientation to the evolving nephrology and urology devices environment highlighting clinical drivers, technology convergence, and strategic considerations for stakeholders
The medical device landscape for nephrology and urology is evolving rapidly as clinicians, payers, and technology providers respond to demographic shifts, rising chronic kidney disease prevalence, and advances in minimally invasive therapies. Devices spanning catheters, dialysis platforms, endoscopes, lithotripsy systems, and ureteral stents now intersect across outpatient, home, and hospital environments, driving new clinical pathways and procurement models. Clinical priorities emphasize patient-centric care, infection control, and efficient resource utilization, while technology trends focus on remote monitoring, minimally invasive energy delivery, and filtration innovations that enable safer and more convenient treatment regimens.
This report introduces the structural and strategic considerations that stakeholders must weigh in the near term. It highlights how convergence between device functionality and service delivery reshapes competitive advantage, and how regulatory and reimbursement pressures are accelerating design-for-value approaches. The introduction sets the stage for deeper examination of market shifts, tariff impacts, segmentation insights, regional differences, company strategies, and recommended actions for industry leaders seeking to navigate this dynamic environment. By framing the core themes upfront, readers will benefit from a coherent baseline that informs subsequent analysis and supports decision-making across commercial, clinical, and operational domains.
How decentralization of care, value-based procurement, and integration of digital monitoring are jointly reshaping product design, adoption pathways, and competitive strategies
The landscape is undergoing transformative shifts driven by several converging forces that alter how devices are developed, procured, and used in clinical practice. First, care delivery is decentralizing as dialysis and postoperative management increasingly move from in-center locations to home settings, prompting manufacturers to redesign devices for ease of use, connectivity, and safety outside traditional hospital infrastructure. Simultaneously, energy-based modalities and advanced filtration technologies are refining procedural effectiveness while reducing recovery time, which encourages ambulatory and outpatient adoption. Regulatory emphasis on patient safety and real-world evidence is pushing companies to embed data capture and remote monitoring capabilities into device lifecycles, thereby blurring lines between products and services.
Additionally, value-based procurement is reshaping purchasing decisions across hospitals, dialysis centers, and ambulatory surgical venues, creating opportunities for bundled offerings and performance-based contracts. Supply chain digitalization and additive manufacturing are providing flexibility in component sourcing and production scale-down, allowing faster iteration and localized manufacture of critical components. Taken together, these shifts favor agile organizations that integrate clinical insight, digital technology, and service-oriented business models, and they place a premium on partnerships that accelerate market entry and adoption.
Navigating 2025 tariff disruptions that are driving supply chain reshaping, design trade-offs, and strategic procurement adjustments across device manufacturers and health systems
The introduction of tariffs on certain medical device components and finished goods in 2025 has introduced a complex set of operational and strategic consequences for manufacturers, suppliers, and healthcare providers. Tariff-induced cost pressures increase the importance of supply chain resilience and supplier diversification, as organizations reassess single-source dependencies and consider nearshoring options to mitigate exposure. In response, procurement teams are negotiating longer-term contracts, seeking price protection clauses, and prioritizing suppliers with transparent cost structures. At the same time, manufacturers face decisions about whether to absorb incremental costs, restructure distribution models, or pass expenses along to purchasers, each of which carries implications for pricing, competitiveness, and hospital purchasing cycles.
Beyond direct cost effects, tariffs influence product design and material selection as companies explore substitute materials, modular architectures, and design simplification to reduce reliance on tariff-impacted inputs. Regulatory compliance pathways may lengthen when manufacturing footprints shift across jurisdictions, and companies must plan for extended timelines for device registration and quality audits. Clinically, procurement variability can lead healthcare systems to favor devices that demonstrate clear operational efficiencies or long-term total cost-of-care benefits, thereby amplifying the importance of robust clinical and economic evidence. Overall, the tariffs act as a catalyst for structural change in sourcing, manufacturing footprint, and commercial models, and stakeholders who proactively redesign supply chains and value propositions will be better positioned to sustain adoption and growth.
Integrated segmentation insights connecting product categories, clinical applications, end-user settings, enabling technologies, and distribution channels to guide prioritization and portfolio strategy
Segmentation analysis reveals how product categories, clinical applications, end-user environments, enabling technologies, and distribution pathways generate distinct adoption dynamics and strategic priorities within the nephrology and urology device space. Product segmentation covers catheters, dialysis devices, endoscopes, lithotripsy systems, and ureteral stents, with dialysis devices further differentiated into continuous renal replacement therapies, hemodiafilters, hemodialysis platforms, and peritoneal dialysis systems, while hemodialysis platforms are defined by home and in-center settings; this product structure highlights where incremental innovation and usability improvements can unlock adoption in both institutional and home contexts. Application-focused segmentation spans kidney failure management, kidney stone removal, prostate disorders, and urinary incontinence management, and within kidney failure management the distinctions among continuous renal replacement therapy, hemodialysis, and peritoneal dialysis reveal disparate clinical workflows and device complexity that inform training and support needs, whereas kidney stone removal subsegments such as extracorporeal shock wave lithotripsy and laser lithotripsy emphasize differing capital requirements and procedural throughput.
End users range from ambulatory surgical centers to dialysis centers, home care settings, and hospitals, each presenting unique procurement cycles, clinical staffing constraints, and infrastructure requirements that shape product specifications and service models. Technology segmentation includes acoustic wave, electrochemical, laser, and ultrafiltration technologies, indicating varying regulatory and adoption pathways as well as distinct evidence-generation needs. Distribution channels span direct sales, distributors, and e-commerce, and the choice of channel has direct implications for customer support, training, and lifecycle revenue. When taken together, these segmentation lenses enable clearer prioritization of product development, go-to-market investments, and clinical evidence portfolios that align with end-user workflows and reimbursement realities.
Regional playbooks for Americas, Europe Middle East & Africa, and Asia-Pacific that align regulatory, clinical, and commercial priorities to accelerate device adoption and access
Regional dynamics shape adoption pathways, regulatory complexity, and commercial models, with the Americas exhibiting different drivers than markets in Europe, Middle East & Africa and Asia-Pacific. In the Americas, provider consolidation, sizeable dialysis networks, and a strong focus on home-based therapies accelerate interest in devices designed for remote monitoring, simplified setup, and infection control, while payer engagement and reimbursement mechanisms influence hospital and outpatient procurement cycles. By contrast, Europe, Middle East & Africa face a mosaic of regulatory regimes and price-sensitive procurement environments that favor durable devices with clear cost-of-care advantages and that benefit from localized clinical evidence and centralized health technology assessment engagement. The Asia-Pacific region demonstrates rapid uptake of minimally invasive technologies and ambulatory solutions, driven by demographic shifts and expanding private healthcare provision, but it also requires adaptable commercial strategies to account for varied regulatory timelines and distribution complexities.
Across these regions, partnerships with regional distributors or service providers often accelerate market access and adoption, and investments in training, local evidence generation, and supply chain localization frequently determine commercial success. Thus, a differentiated regional playbook that aligns regulatory, clinical, and operational priorities is essential to capture opportunity and manage risk effectively.
How leading companies are aligning product modularity, regional manufacturing, data-enabled post-market evidence, and channel strategies to sustain commercial advantage
Key company trends reflect strategic positioning around clinical differentiation, manufacturing flexibility, and commercial channel optimization. Industry leaders are increasingly investing in modular device platforms that support a range of clinical scenarios while enabling economies of scale in component sourcing and regulatory submissions. Strategic partnerships with technology firms and clinical networks accelerate integration of remote monitoring features and data analytics into device ecosystems, thereby strengthening post-market surveillance and justification for value-based contracting. Companies are also prioritizing operational resilience by diversifying supplier bases and evaluating regional manufacturing to buffer against trade disruptions and tariff effects.
Commercially, firms that combine direct sales capabilities with selective distributor partnerships and digital sales enablement tend to gain faster entry into ambulatory and home-care channels. Evidence-generation strategies are shifting toward pragmatic clinical trials and real-world data collection to demonstrate comparative effectiveness and economic value in routine practice settings. Finally, leadership teams that align R&D investment to user-centered design-particularly for home and ambulatory scenarios-are better positioned to win long-term adoption because their products reduce training burden and integrate into care workflows more seamlessly.
Prioritized, pragmatic actions for manufacturers and providers to enhance supply chain resilience, accelerate home and ambulatory adoption, and strengthen evidence-driven contracting
Industry leaders should pursue a set of pragmatic, prioritized actions that improve resilience, accelerate adoption, and reinforce value propositions. First, companies must rearchitect supply chains to include multiple qualified suppliers, nearshore capacity where feasible, and inventory strategies that smooth production during tariff-driven volatility. Second, product development should prioritize usability for home and ambulatory settings, integrating remote monitoring and simplified user interfaces to reduce clinical training needs and support telehealth models. Third, commercial teams need to craft differentiated channel strategies that combine direct clinical engagement with selective distributor partnerships and digital commerce to reach end users across hospitals, dialysis centers, ambulatory surgical sites, and home care programs.
Additionally, organizations should invest in robust real-world evidence programs that link clinical outcomes to operational and economic metrics, enabling stronger contracting conversations with payers and health systems. Finally, leadership must cultivate cross-functional execution capabilities that unite regulatory, clinical affairs, supply chain, and commercial teams so that product launches and post-market expansions proceed efficiently. By following these prioritized steps, companies can mitigate near-term trade disruptions while building the foundation for sustainable market access and adoption.
A transparent, evidence-focused methodology blending clinician and procurement interviews with secondary literature and scenario analysis to produce actionable strategic insights
The research methodology combines targeted primary research, comprehensive secondary analysis, and rigorous synthesis to ensure findings reflect clinical reality and commercial practicality. Primary inputs include structured interviews with clinicians, procurement leaders, technical end users, and device operations managers to capture firsthand insights about workflow constraints, training requirements, and product performance priorities. Secondary research encompasses peer-reviewed clinical literature, regulatory guidance documents, practice guidelines, and manufacturer technical documentation to triangulate clinical claims, safety profiles, and technology fundamentals. Data validation steps include cross-referencing interview findings with public regulatory filings and clinical outcomes literature to identify convergent themes and to flag areas where evidence remains limited.
Analytical methods apply qualitative thematic coding for interview data and scenario-based impact analysis to evaluate how regulatory changes, tariff pressures, and technology adoption pathways may affect strategic choices. Assumptions are explicitly documented and all major qualitative propositions are backed by cited literature or primary-source testimony. Throughout, emphasis is placed on actionable insights rather than abstract modeling so that stakeholders can apply recommendations to commercialization, clinical engagement, and operational planning with confidence.
A decisive synthesis of disruption and opportunity highlighting how adaptive product design, resilient supply chains, and evidence generation will define leadership in device adoption
In conclusion, the nephrology and urology devices landscape is being reshaped by decentralization of care, tariff-induced supply chain recalibration, and the integration of digital and energy-based technologies that drive procedural efficiency and patient convenience. These dynamics create both disruption and opportunity: disruption in the form of increased procurement complexity and cost pressures, and opportunity for firms that align product design with outpatient and home workflows, invest in resilient manufacturing footprints, and generate robust real-world evidence linking clinical outcomes to economic value. Stakeholders who proactively redesign their commercial models, prioritize partnerships for regional access, and accelerate evidence generation will be best positioned to convert near-term headwinds into long-term competitive advantage.
Decision-makers should view the current period as an inflection point to reexamine portfolio priorities, strengthen cross-functional execution, and engage clinicians early in design and adoption planning. By doing so, organizations can reduce time-to-adoption, improve patient outcomes, and create sustainable value across the continuum of care.
Note: PDF & Excel + Online Access - 1 Year
A concise orientation to the evolving nephrology and urology devices environment highlighting clinical drivers, technology convergence, and strategic considerations for stakeholders
The medical device landscape for nephrology and urology is evolving rapidly as clinicians, payers, and technology providers respond to demographic shifts, rising chronic kidney disease prevalence, and advances in minimally invasive therapies. Devices spanning catheters, dialysis platforms, endoscopes, lithotripsy systems, and ureteral stents now intersect across outpatient, home, and hospital environments, driving new clinical pathways and procurement models. Clinical priorities emphasize patient-centric care, infection control, and efficient resource utilization, while technology trends focus on remote monitoring, minimally invasive energy delivery, and filtration innovations that enable safer and more convenient treatment regimens.
This report introduces the structural and strategic considerations that stakeholders must weigh in the near term. It highlights how convergence between device functionality and service delivery reshapes competitive advantage, and how regulatory and reimbursement pressures are accelerating design-for-value approaches. The introduction sets the stage for deeper examination of market shifts, tariff impacts, segmentation insights, regional differences, company strategies, and recommended actions for industry leaders seeking to navigate this dynamic environment. By framing the core themes upfront, readers will benefit from a coherent baseline that informs subsequent analysis and supports decision-making across commercial, clinical, and operational domains.
How decentralization of care, value-based procurement, and integration of digital monitoring are jointly reshaping product design, adoption pathways, and competitive strategies
The landscape is undergoing transformative shifts driven by several converging forces that alter how devices are developed, procured, and used in clinical practice. First, care delivery is decentralizing as dialysis and postoperative management increasingly move from in-center locations to home settings, prompting manufacturers to redesign devices for ease of use, connectivity, and safety outside traditional hospital infrastructure. Simultaneously, energy-based modalities and advanced filtration technologies are refining procedural effectiveness while reducing recovery time, which encourages ambulatory and outpatient adoption. Regulatory emphasis on patient safety and real-world evidence is pushing companies to embed data capture and remote monitoring capabilities into device lifecycles, thereby blurring lines between products and services.
Additionally, value-based procurement is reshaping purchasing decisions across hospitals, dialysis centers, and ambulatory surgical venues, creating opportunities for bundled offerings and performance-based contracts. Supply chain digitalization and additive manufacturing are providing flexibility in component sourcing and production scale-down, allowing faster iteration and localized manufacture of critical components. Taken together, these shifts favor agile organizations that integrate clinical insight, digital technology, and service-oriented business models, and they place a premium on partnerships that accelerate market entry and adoption.
Navigating 2025 tariff disruptions that are driving supply chain reshaping, design trade-offs, and strategic procurement adjustments across device manufacturers and health systems
The introduction of tariffs on certain medical device components and finished goods in 2025 has introduced a complex set of operational and strategic consequences for manufacturers, suppliers, and healthcare providers. Tariff-induced cost pressures increase the importance of supply chain resilience and supplier diversification, as organizations reassess single-source dependencies and consider nearshoring options to mitigate exposure. In response, procurement teams are negotiating longer-term contracts, seeking price protection clauses, and prioritizing suppliers with transparent cost structures. At the same time, manufacturers face decisions about whether to absorb incremental costs, restructure distribution models, or pass expenses along to purchasers, each of which carries implications for pricing, competitiveness, and hospital purchasing cycles.
Beyond direct cost effects, tariffs influence product design and material selection as companies explore substitute materials, modular architectures, and design simplification to reduce reliance on tariff-impacted inputs. Regulatory compliance pathways may lengthen when manufacturing footprints shift across jurisdictions, and companies must plan for extended timelines for device registration and quality audits. Clinically, procurement variability can lead healthcare systems to favor devices that demonstrate clear operational efficiencies or long-term total cost-of-care benefits, thereby amplifying the importance of robust clinical and economic evidence. Overall, the tariffs act as a catalyst for structural change in sourcing, manufacturing footprint, and commercial models, and stakeholders who proactively redesign supply chains and value propositions will be better positioned to sustain adoption and growth.
Integrated segmentation insights connecting product categories, clinical applications, end-user settings, enabling technologies, and distribution channels to guide prioritization and portfolio strategy
Segmentation analysis reveals how product categories, clinical applications, end-user environments, enabling technologies, and distribution pathways generate distinct adoption dynamics and strategic priorities within the nephrology and urology device space. Product segmentation covers catheters, dialysis devices, endoscopes, lithotripsy systems, and ureteral stents, with dialysis devices further differentiated into continuous renal replacement therapies, hemodiafilters, hemodialysis platforms, and peritoneal dialysis systems, while hemodialysis platforms are defined by home and in-center settings; this product structure highlights where incremental innovation and usability improvements can unlock adoption in both institutional and home contexts. Application-focused segmentation spans kidney failure management, kidney stone removal, prostate disorders, and urinary incontinence management, and within kidney failure management the distinctions among continuous renal replacement therapy, hemodialysis, and peritoneal dialysis reveal disparate clinical workflows and device complexity that inform training and support needs, whereas kidney stone removal subsegments such as extracorporeal shock wave lithotripsy and laser lithotripsy emphasize differing capital requirements and procedural throughput.
End users range from ambulatory surgical centers to dialysis centers, home care settings, and hospitals, each presenting unique procurement cycles, clinical staffing constraints, and infrastructure requirements that shape product specifications and service models. Technology segmentation includes acoustic wave, electrochemical, laser, and ultrafiltration technologies, indicating varying regulatory and adoption pathways as well as distinct evidence-generation needs. Distribution channels span direct sales, distributors, and e-commerce, and the choice of channel has direct implications for customer support, training, and lifecycle revenue. When taken together, these segmentation lenses enable clearer prioritization of product development, go-to-market investments, and clinical evidence portfolios that align with end-user workflows and reimbursement realities.
Regional playbooks for Americas, Europe Middle East & Africa, and Asia-Pacific that align regulatory, clinical, and commercial priorities to accelerate device adoption and access
Regional dynamics shape adoption pathways, regulatory complexity, and commercial models, with the Americas exhibiting different drivers than markets in Europe, Middle East & Africa and Asia-Pacific. In the Americas, provider consolidation, sizeable dialysis networks, and a strong focus on home-based therapies accelerate interest in devices designed for remote monitoring, simplified setup, and infection control, while payer engagement and reimbursement mechanisms influence hospital and outpatient procurement cycles. By contrast, Europe, Middle East & Africa face a mosaic of regulatory regimes and price-sensitive procurement environments that favor durable devices with clear cost-of-care advantages and that benefit from localized clinical evidence and centralized health technology assessment engagement. The Asia-Pacific region demonstrates rapid uptake of minimally invasive technologies and ambulatory solutions, driven by demographic shifts and expanding private healthcare provision, but it also requires adaptable commercial strategies to account for varied regulatory timelines and distribution complexities.
Across these regions, partnerships with regional distributors or service providers often accelerate market access and adoption, and investments in training, local evidence generation, and supply chain localization frequently determine commercial success. Thus, a differentiated regional playbook that aligns regulatory, clinical, and operational priorities is essential to capture opportunity and manage risk effectively.
How leading companies are aligning product modularity, regional manufacturing, data-enabled post-market evidence, and channel strategies to sustain commercial advantage
Key company trends reflect strategic positioning around clinical differentiation, manufacturing flexibility, and commercial channel optimization. Industry leaders are increasingly investing in modular device platforms that support a range of clinical scenarios while enabling economies of scale in component sourcing and regulatory submissions. Strategic partnerships with technology firms and clinical networks accelerate integration of remote monitoring features and data analytics into device ecosystems, thereby strengthening post-market surveillance and justification for value-based contracting. Companies are also prioritizing operational resilience by diversifying supplier bases and evaluating regional manufacturing to buffer against trade disruptions and tariff effects.
Commercially, firms that combine direct sales capabilities with selective distributor partnerships and digital sales enablement tend to gain faster entry into ambulatory and home-care channels. Evidence-generation strategies are shifting toward pragmatic clinical trials and real-world data collection to demonstrate comparative effectiveness and economic value in routine practice settings. Finally, leadership teams that align R&D investment to user-centered design-particularly for home and ambulatory scenarios-are better positioned to win long-term adoption because their products reduce training burden and integrate into care workflows more seamlessly.
Prioritized, pragmatic actions for manufacturers and providers to enhance supply chain resilience, accelerate home and ambulatory adoption, and strengthen evidence-driven contracting
Industry leaders should pursue a set of pragmatic, prioritized actions that improve resilience, accelerate adoption, and reinforce value propositions. First, companies must rearchitect supply chains to include multiple qualified suppliers, nearshore capacity where feasible, and inventory strategies that smooth production during tariff-driven volatility. Second, product development should prioritize usability for home and ambulatory settings, integrating remote monitoring and simplified user interfaces to reduce clinical training needs and support telehealth models. Third, commercial teams need to craft differentiated channel strategies that combine direct clinical engagement with selective distributor partnerships and digital commerce to reach end users across hospitals, dialysis centers, ambulatory surgical sites, and home care programs.
Additionally, organizations should invest in robust real-world evidence programs that link clinical outcomes to operational and economic metrics, enabling stronger contracting conversations with payers and health systems. Finally, leadership must cultivate cross-functional execution capabilities that unite regulatory, clinical affairs, supply chain, and commercial teams so that product launches and post-market expansions proceed efficiently. By following these prioritized steps, companies can mitigate near-term trade disruptions while building the foundation for sustainable market access and adoption.
A transparent, evidence-focused methodology blending clinician and procurement interviews with secondary literature and scenario analysis to produce actionable strategic insights
The research methodology combines targeted primary research, comprehensive secondary analysis, and rigorous synthesis to ensure findings reflect clinical reality and commercial practicality. Primary inputs include structured interviews with clinicians, procurement leaders, technical end users, and device operations managers to capture firsthand insights about workflow constraints, training requirements, and product performance priorities. Secondary research encompasses peer-reviewed clinical literature, regulatory guidance documents, practice guidelines, and manufacturer technical documentation to triangulate clinical claims, safety profiles, and technology fundamentals. Data validation steps include cross-referencing interview findings with public regulatory filings and clinical outcomes literature to identify convergent themes and to flag areas where evidence remains limited.
Analytical methods apply qualitative thematic coding for interview data and scenario-based impact analysis to evaluate how regulatory changes, tariff pressures, and technology adoption pathways may affect strategic choices. Assumptions are explicitly documented and all major qualitative propositions are backed by cited literature or primary-source testimony. Throughout, emphasis is placed on actionable insights rather than abstract modeling so that stakeholders can apply recommendations to commercialization, clinical engagement, and operational planning with confidence.
A decisive synthesis of disruption and opportunity highlighting how adaptive product design, resilient supply chains, and evidence generation will define leadership in device adoption
In conclusion, the nephrology and urology devices landscape is being reshaped by decentralization of care, tariff-induced supply chain recalibration, and the integration of digital and energy-based technologies that drive procedural efficiency and patient convenience. These dynamics create both disruption and opportunity: disruption in the form of increased procurement complexity and cost pressures, and opportunity for firms that align product design with outpatient and home workflows, invest in resilient manufacturing footprints, and generate robust real-world evidence linking clinical outcomes to economic value. Stakeholders who proactively redesign their commercial models, prioritize partnerships for regional access, and accelerate evidence generation will be best positioned to convert near-term headwinds into long-term competitive advantage.
Decision-makers should view the current period as an inflection point to reexamine portfolio priorities, strengthen cross-functional execution, and engage clinicians early in design and adoption planning. By doing so, organizations can reduce time-to-adoption, improve patient outcomes, and create sustainable value across the continuum of care.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
190 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Artificial intelligence–driven urine biomarker analysis platforms enabling real-time kidney disease screening
- 5.2. Development of biodegradable ureteral stents with controlled on-demand drug elution properties
- 5.3. Introduction of wearable continuous renal function monitors for early chronic kidney disease detection
- 5.4. Integration of telemedicine platforms in remote peritoneal dialysis management and patient coaching
- 5.5. Adoption of 3D printed patient-specific renal vascular grafts for complex reconstructive procedures
- 5.6. Advances in nanoparticle-based targeted drug delivery systems for polycystic kidney disease therapy
- 5.7. Deployment of robotic-assisted minimally invasive technologies in complex urolithiasis and prostate surgeries
- 5.8. Emergence of smart home hemodialysis devices with AI-powered ultrafiltration and treatment personalization
- 5.9. Implementation of predictive analytics in continuous renal replacement therapy machines to optimize fluid removal
- 5.10. Expansion of digital health applications for post-transplant urological patient monitoring and compliance management
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Nephrology & Urology Devices Market, by Product
- 8.1. Catheters
- 8.2. Dialysis Devices
- 8.2.1. CrRt Systems
- 8.2.2. Hemodiafilters
- 8.2.3. Hemodialysis Systems
- 8.2.4. Peritoneal Dialysis Systems
- 8.3. Endoscopes
- 8.4. Lithotripsy Devices
- 8.5. Ureteral Stents
- 9. Nephrology & Urology Devices Market, by Technology
- 9.1. Acoustic Wave Technologies
- 9.2. Electrochemical Technologies
- 9.3. Laser Technologies
- 9.4. Ultrafiltration Technologies
- 10. Nephrology & Urology Devices Market, by Distribution Channel
- 10.1. Direct Sales
- 10.2. Distributors
- 10.3. Ecommerce
- 11. Nephrology & Urology Devices Market, by Application
- 11.1. Kidney Failure Management
- 11.1.1. CrRt
- 11.1.2. Hemodialysis
- 11.1.3. Peritoneal Dialysis
- 11.2. Kidney Stone Removal
- 11.2.1. Extracorporeal Shock Wave Lithotripsy
- 11.2.2. Laser Lithotripsy
- 11.3. Prostate Disorders
- 11.4. Urinary Incontinence Management
- 12. Nephrology & Urology Devices Market, by End User
- 12.1. Ambulatory Surgical Centers
- 12.2. Dialysis Centers
- 12.3. Home Care Settings
- 12.4. Hospitals
- 13. Nephrology & Urology Devices Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Nephrology & Urology Devices Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Nephrology & Urology Devices Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Asahi Kasei Corporation
- 16.3.2. B. Braun Melsungen AG
- 16.3.3. Baxter International Inc.
- 16.3.4. Becton, Dickinson and Company
- 16.3.5. Boston Scientific Corporation
- 16.3.6. Coloplast A/S
- 16.3.7. Convatec Group plc
- 16.3.8. Cook Group Incorporated
- 16.3.9. Dornier MedTech
- 16.3.10. Fresenius Medical Care AG & Co. KGaA
- 16.3.11. Hollister Incorporated
- 16.3.12. Medtronic plc
- 16.3.13. Nipro Corporation
- 16.3.14. Olympus Corporation
- 16.3.15. Siemens Healthineers AG
- 16.3.16. Stryker Corporation
- 16.3.17. Teleflex Incorporated
- 16.3.18. Terumo Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
